Clinical Trial Update: IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating IBI351 in combination with Cetuximab beta for untreated advanced non-small cell lung cancer with KRAS G12C mutation. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IBI351

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Lung Cancer (Non-Small Cell) | Phase 2 | Status: RECRUITING